Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction
Chan Soon Park(Korea Advanced Institute of Science and Technology), Dong‐Ju Choi(Inserm), Eun‐Seok Jeon, Jae‐Joong Kim(Inje University), Kye Hun Kim(Chonnam National University), Sang Hong Baek(University of California, Los Angeles), Byung‐Su Yoo(University of San Diego), Myeong‐Chan Cho(Korea National Institute of Health), Il‐Young Oh(Seoul National University Bundang Hospital), Byung‐Hee Oh(Sejong General Hospital), Seok‐Min Kang(Harvard University), Hyun Ah Park(Inje University Seoul Paik Hospital), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Shung Chull Chae(Kyungpook National University Hospital), Jin Joo Park(Seoul National University Bundang Hospital), Hyun‐Jai Cho(Seoul National University Hospital), Hae‐Young Lee(Seoul National University Hospital)
Cited by 113
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k